This study appeared in the July 22nd edition of the Journal of the American Medical Association. Certain CSF fluid markers can now justify arly-stage Alzheimer's disease. These are
- beta-amyloid 42 (Aß42)
- T-tau,
- P-tau
The study had 2 parts — a cross-sectional component and a prospective evaluation.The cross-sectional phase of the study identified biomarker cutoff levels in patients with AD and controls. The prospective phase evaluated patients with cognitive impairment from 12 centers in the United States and Europe.
A total of 750 patients with mild cognitive impairment, 529 with AD (Alzheimer's Disease), and 304 controls were surveyed
0 comments
Post a Comment